Stocks · News reference

Cognition Therapeutics Q2 EPS $(0.04) Beats $(0.06) Estimate

Aug 6, 2026, 9:13 PMBenzinga Newsdesk

Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 63.64 percent increase over losses of $(0.11) per

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CGTX

Source: benzinga
Observed: Aug 6, 2026, 9:13 PM
Checked: Aug 6, 2026, 9:13 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaJun 24, 2026, 11:39 AMBenzinga Newsdesk
FDA Agrees Psychosis Associated With Dementia With Lewy Bodies May Be Approvable Outcome, Reaches Alignment With Cognition Therapeutics On Vital Aspects To Support Its New Drug Application
CGTX
SEC EDGARJun 24, 2026, 11:39 AMSEC EDGAR
8-K filing — COGNITION THERAPEUTICS INC (CGTX)
Filed: 2026-06-24 AccNo: 0001104659-26-077060 Size: 218 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
CGTX
BenzingaJun 16, 2026, 11:32 AMBenzinga Newsdesk
Cognition Therapeutics Receives Notice Of Allowance From USPTO For Patent Application 19/563,468, Covering Polymorphic Crystalline Form Of Zervimesine
CGTX

Cognition Therapeutics Q2 EPS $(0.04) Beats $(0.06) Estimate

Connected Markets

Related Headlines

FDA Agrees Psychosis Associated With Dementia With Lewy Bodies May Be Approvable Outcome, Reaches Alignment With Cognition Therapeutics On Vital Aspects To Support Its New Drug Application

8-K filing — COGNITION THERAPEUTICS INC (CGTX)

Cognition Therapeutics Receives Notice Of Allowance From USPTO For Patent Application 19/563,468, Covering Polymorphic Crystalline Form Of Zervimesine